Financial Health Assessment: ISANSYS LIFECARE LIMITED

1. Financial Health Score: F

Explanation: This company is in critical condition – the equivalent of a patient in intensive care requiring life support. With net liabilities exceeding £11 million, consistent and deepening losses, and a company status of "Liquidation," the financial vitals indicate terminal distress. The business is entirely dependent on external shareholder funding (principally Zip Address Ltd) to remain operational, and is actively seeking an acquirer as its survival strategy.

2. Key Vital Signs

Additional Vital Signs of Concern:

• Net Current Liabilities: (£2,425,998) – The company has no working capital cushion; current liabilities far exceed current assets
• Long-term Creditors: £10,825,000 – Predominantly convertible loans from shareholders, representing the "life support" mechanism
• Other Loans (due within one year): £2,371,841 – Significant short-term debt obligations
• Trade Debtors: £214,055 (up from £154,392) – Some revenue activity, but insufficient to stem losses

3. Diagnosis

Symptoms Analysis

Chronic Insolvency: This is not a new condition – it is a progressive, long-term illness. The financial history reveals a consistent pattern of deepening insolvency:

The "patient" has been bleeding equity for seven consecutive years, with cumulative losses now exceeding £12 million on share capital of just £252.

Life Support Dependency: The company's going concern basis is explicitly dependent on convertible loans from Zip Address Ltd, with a Comfort Letter covering only 12 months. This is the financial equivalent of a patient on a ventilator – survival depends entirely on external intervention that can be withdrawn.

Minimal Organic Revenue Generation: With only £91,953 in cash, trade debtors of £214,055, and stocks of £50,793, the company's current asset base totals approximately £399,217 against current liabilities of £2,825,215. The revenue-generating capacity appears insufficient to sustain operations without continued external funding.

Asset Quality Concerns: While total assets show £2.45M, the composition is concerning: - Intangible assets (patents/licences): £322,905 – significant additions of £127,652 suggest continued R&D investment, but these are illiquid and difficult to realise - Investments in subsidiaries: £1,721,346 – represents the largest asset; however, the realisable value and quality of these investments is uncertain given the parent's own financial distress - Tangible assets: only £11,647 – minimal physical asset base

Escalating Short-Term Obligations: Current liabilities have surged from £1.9M to £2.8M, with other loans (likely related party) representing £2.37M due within one year. This suggests previously long-term convertible loans may be reclassified as current, or additional short-term borrowing has occurred.

Overall Diagnosis: Terminal Insolvency without External Intervention

The company is insolvent on both a net assets basis and a net current assets basis. It cannot meet its obligations as they fall due without continued shareholder funding. The business model, while operating in the potentially attractive medical device technology space, has not achieved commercial viability after 13+ years of operation. The company is now in "Liquidation" status according to Companies House, which suggests the formal wind-down process may have commenced or be imminent.

4. Recommendations

Immediate Actions (Critical Care)

1. Clarify Liquidation Status: The Companies House status shows "Liquidation" – stakeholders must urgently determine whether voluntary liquidation proceedings have commenced, what type (CVL, MVL), and who the appointed liquidator is. This fundamentally changes the decision-making framework.

2. Protect Creditor Interests: If formal liquidation has not yet begun, directors must be extremely careful not to trade whilst insolvent, as this creates personal liability risk for wrongful trading under the Insolvency Act 1986.

3. Accelerate Sale Process: The directors' stated strategy of seeking an acquirer should be pursued with maximum urgency. Given the liquidation status, this may now need to be handled through the liquidator.

If Sale is Still Viable

4. Asset Realisation Strategy: The £1.72M investment in subsidiaries and £322K in intangible assets (patents/technology) represent the primary value. An independent valuation of these assets should be obtained to support sale negotiations.

5. Stakeholder Communication: Maintain transparent communication with Zip Address Ltd and other creditors about the timeline and prospects for realisation of value.

6. Minimise Cash Burn: Reduce operating costs to the absolute minimum necessary to preserve value while seeking an acquirer. Every month of operation increases the deficit.

For Creditors and Stakeholders

7. Assess Recovery Prospects: Unsecured creditors should realistically assess that recovery is unlikely given the £11M+ deficit. If liquidation proceeds, the priority will be secured/preferential creditors.

8. Review Related Party Positions: Given that Zip Address Ltd (connected to the PSC Keith Errey) is the primary creditor, there may be limited recourse for other creditors. Related party creditors currently control the company's fate.

Risk Factors